Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06693726 · ClinicalTrials.gov registry record · Phase 4
Early Angiotensin II in the Emergency Department
A Phase 4 study of Septic Shock, sponsored by Brett A Faine.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06693726 is a Phase 4 study of Septic Shock that is actively recruiting participants, run by Brett A Faine. The registered enrollment target is 20 participants, below the 5,058-participant average among 24 other Septic Shock trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06693726, a Phase 4 study of Septic Shock, is actively recruiting participants, sponsored by Brett A Faine.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study will enroll 20 patients with septic shock and require emergent vasopressor support in the emergency department (ED). The primary objective of the study is to determine the feasibility of early peripheral administration of angiotensin II for treatment of septic shock in the ED
Conditions Studied
Interventions
- DRUG Angiotensin II Infusion
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06693726
The ClinicalTrials.gov registry entry for NCT06693726 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,058-participant average among 24 other Septic Shock trials with a reported enrollment target (100% lower). The listed sponsor is Brett A Faine, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Septic Shock appearing as the primary indexed condition, and to 1 intervention - of which Angiotensin II Infusion is the first listed.
NCT06693726 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT06693726 about?
NCT06693726 is a clinical study titled "Early Angiotensin II in the Emergency Department". This pilot study will enroll 20 patients with septic shock and require emergent vasopressor support in the emergency department (ED). The primary objective of the study is to determine the feasibility of early peripheral administration of angiotensin II for treatment of septic shock in the ED
What is the current status of trial NCT06693726?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2025-04-01. Estimated completion is 2026-11-30.
What conditions does trial NCT06693726 study?
This clinical trial studies the following conditions: Septic Shock.
What interventions are being tested in trial NCT06693726?
The interventions under investigation include: Angiotensin II Infusion (DRUG).
Who is sponsoring clinical trial NCT06693726?
This trial is sponsored by Brett A Faine, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06693726 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Septic Shock
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
RECRUITING · Phase 4
-
Vasopressin for Septic Shock Pragmatic Trial
ACTIVE NOT RECRUITING · Phase 4
-
Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock
COMPLETED · Phase 4
-
Stress Hydrocortisone In Pediatric Septic Shock
RECRUITING · Phase 3
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.